search
Back to results

Use of Oxygen in Heart Failure With Preserved Ejection Fraction (STOP-EF)

Primary Purpose

Heart Failure

Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
oxygen
Sponsored by
Hull University Teaching Hospitals NHS Trust
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Heart Failure

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Over 50 years of age and able and willing to give consent
  • Have signs and/or symptoms of heart failure
  • Left ventricular ejection fraction > 45%
  • NT-pro BNP > 220 pg/ml (in the previous 12 months)
  • On any diuretic

Exclusion Criteria:

  • Unable or unwilling to give consent
  • Recent (<1 month) acute myocardial infarct or cerebrovascular event
  • Significant renal dysfunction (eGFR <30 ml.min-1.1.73m-2)
  • Significant anaemia (Haemoglobin < 100 g.L-1)
  • Systolic blood pressure <90 mmHg, or >180 mmHg
  • Severe mitral or aortic valve disease
  • Diagnosis of severe chronic lung disease
  • Involvement in another medicinal trial within the past four weeks
  • Unable to use cycle
  • Any planned admission in the following 3-4 weeks (patient can be reconsidered for enrolment after planned admission)

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Active Comparator

    Active Comparator

    Active Comparator

    Arm Label

    21% oxygen

    28% oxygen

    40% oxygen

    Arm Description

    room air will be delivered via Venturi mask during cycle ergometry

    28% oxygen will be delivered via Venturi mask during cycle ergometry

    40% oxygen will be delivered via Venturi mask during cycle ergometry

    Outcomes

    Primary Outcome Measures

    change in exercise time with the use of 21%, 28% and 40% oxygen
    the total time cycled in each arm

    Secondary Outcome Measures

    change in shortness of breath with the use of 21%, 28% and 40% oxygen
    shortness of breath measured using BORG score
    change in Peak metabolic equivalent with the use of 21%, 28% and 40% oxygen
    measured using standard peak metabolic equivalent

    Full Information

    First Posted
    October 3, 2016
    Last Updated
    June 24, 2019
    Sponsor
    Hull University Teaching Hospitals NHS Trust
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02949531
    Brief Title
    Use of Oxygen in Heart Failure With Preserved Ejection Fraction
    Acronym
    STOP-EF
    Official Title
    Randomised, Cross Over, Single Blind, Control Trial of Short Term Oxygen Use During Cycle Ergometry in Patients With Chronic Heart Failure With Preserved Ejection Fraction
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2016
    Overall Recruitment Status
    Completed
    Study Start Date
    November 3, 2016 (Actual)
    Primary Completion Date
    February 15, 2017 (Actual)
    Study Completion Date
    February 15, 2017 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Hull University Teaching Hospitals NHS Trust

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Oxygen is routinely given to patients with common conditions such as COPD and heart failure. There is no evidence behind giving oxygen to patients specifically in heart failure due to a stiff heart. This study aims to explore the effect oxygen has on the ability of patients with chronic heart failure and the ability to exercise. Other common variables will be assessed such as heart rate and blood pressure to observe the response to varying concentrations of oxygen. The concentrations chosen are commonly offered in hospitals and indeed are being delivered through standard equipment found in all hospitals in the country. It is hoped that studying the effect of short term oxygen on patients with heart failure will help to identify the effectiveness of oxygen in longer term therapy for patients who are often breathless with a decreased exercise tolerance.
    Detailed Description
    Many patients with reduced exercise tolerance have a preserved left ventricular function. These patients are labelled as having heart failure with preserved ejection fraction (HeFPEF), when the combined use of echocardiography and biochemistry. The prevalence and the incidence of HeFPEF are on the increase and currently it accounts for around 50% of all patients diagnosed with HF. The last twenty years of research has led to great improvement in available treatments for heart failure with reduced ejection fraction (HeFREF); however, current guidelines only suggest diuretics to improve symptoms of those patients with HeFPEF: clinical trials of several pharmacological interventions have failed to show convincing reductions in morbidity or mortality for patients with HeFPEF. The effect of oxygen therapy on exercise capacity has remained poorly understood in HeFREF and, at the time of writing this study, it has never been explored in HeFPEF. The investigators recently completed a study showing an increase in exercise time, exercise load at peak exercise and peak metabolic equivalent on cycle ergometry with 28% oxygen supplementation and further increments when 40% oxygen supplementation was used in patients with heart failure with reduced ejection fraction. The investigators aim to improve exercise time in patients with HeFPEF with oxygen supplementation. Identifying the correct dose of oxygen will be a further aim to avoid hyperoxygenation but provide adequate oxygen to improve exercise tolerance. Patients will be identified from heart failure clinics and will be invited for screening visit. Eligible patients will have three treatment visit at least one week apart (each visit with a different oxygen concentration i.e room air, 28% and 40% oxygen, randomly determined by sealed envelopes) Patients will use standard cycle ergometry to exercise and work load will be increased every minute by 5-10 watts. Patients will be encouraged to cycle until tired. At the end of cycling, exercise time, peak metabolic equivalent, work load, shortness of breath score will be noted at each visit.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Heart Failure

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Crossover Assignment
    Masking
    Participant
    Allocation
    Randomized
    Enrollment
    50 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    21% oxygen
    Arm Type
    Active Comparator
    Arm Description
    room air will be delivered via Venturi mask during cycle ergometry
    Arm Title
    28% oxygen
    Arm Type
    Active Comparator
    Arm Description
    28% oxygen will be delivered via Venturi mask during cycle ergometry
    Arm Title
    40% oxygen
    Arm Type
    Active Comparator
    Arm Description
    40% oxygen will be delivered via Venturi mask during cycle ergometry
    Intervention Type
    Drug
    Intervention Name(s)
    oxygen
    Primary Outcome Measure Information:
    Title
    change in exercise time with the use of 21%, 28% and 40% oxygen
    Description
    the total time cycled in each arm
    Time Frame
    at 3 weeks
    Secondary Outcome Measure Information:
    Title
    change in shortness of breath with the use of 21%, 28% and 40% oxygen
    Description
    shortness of breath measured using BORG score
    Time Frame
    at 3 weeks
    Title
    change in Peak metabolic equivalent with the use of 21%, 28% and 40% oxygen
    Description
    measured using standard peak metabolic equivalent
    Time Frame
    at 3 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    50 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Over 50 years of age and able and willing to give consent Have signs and/or symptoms of heart failure Left ventricular ejection fraction > 45% NT-pro BNP > 220 pg/ml (in the previous 12 months) On any diuretic Exclusion Criteria: Unable or unwilling to give consent Recent (<1 month) acute myocardial infarct or cerebrovascular event Significant renal dysfunction (eGFR <30 ml.min-1.1.73m-2) Significant anaemia (Haemoglobin < 100 g.L-1) Systolic blood pressure <90 mmHg, or >180 mmHg Severe mitral or aortic valve disease Diagnosis of severe chronic lung disease Involvement in another medicinal trial within the past four weeks Unable to use cycle Any planned admission in the following 3-4 weeks (patient can be reconsidered for enrolment after planned admission)
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Andrew Clark
    Organizational Affiliation
    Castle Hill Hospital
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    29803343
    Citation
    Shah P, Pellicori P, Rimmer S, Rigby AS, Clark AL. Effect of increased inspired oxygen on exercise performance in patients with heart failure and normal ejection fraction. Int J Cardiol. 2018 Oct 1;268:166-169. doi: 10.1016/j.ijcard.2018.05.029. Epub 2018 May 24.
    Results Reference
    background

    Learn more about this trial

    Use of Oxygen in Heart Failure With Preserved Ejection Fraction

    We'll reach out to this number within 24 hrs